INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study
February 2024 | Volume 23 | Issue 2 | SF405634s5 | Copyright © February 2024
Published online January 31, 2024
Emmy Graber MD MBAa, Hilary E. Baldwin MDb, Richard G. Fried MD PhDc, Evan A. Rieder MDd, Adelaide A. Hebert MDe, James Del Rosso DOf, Leon Kircik MDg, Linda Stein Gold MDh, Julie C. Harper MDi, Andrew F. Alexis MDj, Siva Narayanan PhDk, Volker Koscielny MDl, Ismail Kasujee PhDl
aThe Dermatology Institute of Boston and Northeastern University, Boston, MA
bAcne Treatment and Research Center, Brooklyn, NY
cYardley Dermatology Associates, Yardley, PA; dPrivate Practice, New York, NY; eUT Health McGovern Medical School, Houston, TX;
fJDR Dermatology Research/Thomas Dermatology, Las Vegas, NV; gIcahn School of Medicine, Mount Sinai, New York, NY;
hHenry Ford Health System, Bloomfield, MI; iThe Dermatology and Skin Care Center of Birmingham, Birmingham, AL;
jWeill Cornell Medical College, New York, NY; kAvant Health LLC, Bethesda, MD; lAlmirall SA, Barcelona, Spain
judged due to AV, 27.3% reported concerns about their ability to reach future goals, and 27.7% reported sleep impact. The majority reported adequate parental understanding of AV concerns (for patients <18 years old; Figure 3a and 3b).
Disease Burden After 12 Weeks of Treatment With Sarecycline Following 12 weeks of treatment, there was a significant increase (P ≤.0001) in the proportions of patients responding that they never/rarely: felt angry (31.6%); worried about AV worsening (28.9%); had thoughts about AV (20.9%); had a certain level of worries about AV (38.7%); altered their social media/selfie activity (23.7%); had an impact on real-life plans due to AV (22.9%); made efforts to hide AV (21.3%); felt picked-on/judged due to AV (15.0%); were concerned about their ability to reach future goals due to AV (13.8%); or had their sleep impacted due to AV (18.2%) (Figure 3a and 3b).
